115 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
is investigating (Z)-endoxifen in premenopausal women with measurable breast density. Participants receive daily doses of (Z)-endoxifen for six months, over … to offer women diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
)-endoxifen in premenopausal women with measurable breast density. Participants receive daily doses of (Z)-endoxifen for six months, over the course … for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS) study is an ongoing Phase 2 platform study designed to offer women
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
12 Mar 24
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
8:30am
for hundreds of thousands of women globally each year. Current treatments are often limited by side effects. I believe (Z)-endoxifen has … studies and in a small Phase 2 study of women with breast cancer. (Z)-endoxifen is currently being studied in four Phase 2 trials: one in healthy
8-K
EX-99.1
ex9jsk0c
13 Nov 23
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:00am
8-K
EX-99.1
zio1d87ldyl7
14 Aug 23
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8:30am
8-K
EX-99.1
ud558752vvw2pci5 i9
15 May 23
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:10am
8-K
EX-99.1
fk01kt4odh irs
7 Nov 22
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
EX-99.1
o31v 00revf75or
8 Aug 22
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
q1p6es6g 2a8qlosj3z
1 Jul 22
Regulation FD Disclosure
9:01am
8-K
enr 0bsqgv4
6 Jun 22
Regulation FD Disclosure
2:45pm
8-K
EX-99.1
t8ymsh4q
9 May 22
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
4:00pm